USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/11832
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKeller, Dominic Pascal-
dc.contributor.authorJung, Ioan-
dc.date.accessioned2020-09-30T14:24:04Z-
dc.date.available2020-09-30T14:24:04Z-
dc.date.issued2016-
dc.identifier.citationKELLER, Dominic Pascal, JUNG, Ioan. The angiogenic pathway of glioblastoma. In: MedEspera: the 6th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2016, p. 248.en_US
dc.identifier.isbn978-9975-3028-3-8.-
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/11832-
dc.descriptionUniversity of Medicine and Pharmacy Targu Mures, Romania, The 6th International Medical Congress for Students and Young Doctorsen_US
dc.description.abstractBackground: There are over 130 different types of tumors in the central nervous system that include astrocytoma, glioblastoma, oligodendroglioma, meningioma, and schwannoma. From them, glioblastoma is considered the most common lethal primary brain tumor in adults. Objective: To create an overview of different angiogenic pathways of the glioblastoma. Material and Method: The 277 histopathologically confirmed consecutive primary brain tumors diagnosed at Department of Pathology of Emergency County Hospital of Tirgu-Mures, Romania, during 2012-2013, were retrospectively checked to see the incidence and immunohistochemical (IHC) particularities of glioblastoma. The immunostains were performed in 35 randomly selected glioblastomas, using the angiogenesis-related antibodies Vascular Endothelial Growth Factor (VEGFA), COX-2, Maspin, and Epidermal Growth Factor Receptor (EGFR). Results: From the 277 tumor cases, 62 (22.38%) were glioblastomas. Most of them (85.48%, n=53) were diagnosed in patients over 40, with a male:female ratio of 1.4:1. From the 35 cases used for IHC examinations, only 6 were marked by VEGF (17.14%), the other 29 (82.86%) being VEGF negative. No one of the cases showed maspin posivity. The rate of positivity for EGFR and COX-2 was 37.14% (n=13) and 60% (n=21), respectively. All of the 13 EGFR positive cases displayed COX-2 positivity and did not showed VEGF expression. Conclusions: In glioblastoma cells, the angiogenesis is rather mediated by COX-2 than VEGF or maspin. In patients with VEGF negative glioblasomas, the anti-EGFR drugs could be succesfully used. The effect of anti-EGFR drugs can be improved when combined with anti-COX-2 agents.en_US
dc.language.isoenen_US
dc.publisherMedEsperaen_US
dc.titleThe angiogenic pathway of glioblastomaen_US
dc.typeArticleen_US
Appears in Collections:MedEspera 2016

Files in This Item:
File Description SizeFormat 
The_angiogenic_pathway_of_glioblastoma.pdf266.58 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback